EvaMarieVolfMD

PubMed

• 4 citations
  Tumor Necrosis Factor Inhibitor Primary Failure Predicts Decreased Ustekinumab Efficacy in Psoriasis Patients.
  Eric P. Sorensen, Kristina A. Fanucci, Ami Saraiya, Eva M. Volf, Shiu-chung Au, Yahya Argobi, Ryan Mansfield, Alice B. Gottlieb> ;Journal of Drugs in Dermatology. 2015 Aug 1
• 38 citations
  Prevalence of the Metabolic Syndrome in Children with Psoriatic Disease
  Ari M. Goldminz, Catherine D Buzney, Noori Kim, Shiu-chung Au, Danielle Levine, Andrew C. Wang, Eva M. Volf, Shimrat Yaniv, Todd Kerensky, Manasa Bhandarkar, Nicole Du...> ;Pediatric Dermatology. 2013 Nov 1
• 40 citations
  Investigator-initiated, open-label trial of ustekinumab for the treatment of moderate-to-severe palmoplantar psoriasis.
  Shiu-chung Au, Ari M. Goldminz, Noori Kim, Nicole Dumont, Melissa A Michelon, Eva M. Volf, Meghan T. Hession, Paul F. Lizzul, Israel D. Andrews, Todd Kerensky, Andrew ...> ;The Journal of Dermatological Treatment. 2013 Jun 1
• 40 citations
  Association between pediatric psoriasis and the metabolic syndrome
  Shiu-chung Au, Ari M. Goldminz, Daniel S. Loo, Nicole Dumont, Danielle Levine, Eva M. Volf, Melissa A Michelon, Andrew C. Wang, Noori Kim, Shimrat Yaniv, Paul F. Lizzu...> ;Journal of the American Academy of Dermatology. 2012 Jun 1
• 68 citations
  A phase 2, open-label, investigator-initiated study to evaluate the safety and efficacy of apremilast in subjects with recalcitrant allergic contact or atopic dermatitis.
  Eva M. Volf, Shiu-chung Au, Nicole Dumont, Pamela L. Scheinman, Alice B. Gottlieb> ;Journal of Drugs in Dermatology. 2012 Mar 1
• 9 citations
  Assessor-blinded study of the metabolic syndrome and surrogate markers of increased cardiovascular risk in children with moderate-to-severe psoriasis compared with age...
  Eva M. Volf, Danielle Levine, Melissa A Michelon, Shiu-chung Au, Eshan Patvardhan, Nicole Dumont, Daniel S. Loo, Jeffrey T. Kuvin, Alice B. Gottlieb> ;Journal of Drugs in Dermatology. 2011 Aug 1
• Join now to see all